Oneg Hakarmel

Company Overview

Snapshot

Founded in January 2002 by Prof. Noam Gavriely, Oneg Hakarmel operates with 11–50 employees. The company specializes in medical devices for orthopedic and vascular surgery, as well as emergency medicine. A key milestone was the launch of HemaShock in November 2018, an emergency auto-transfusion tourniquet designed to assist patients experiencing severe shock or cardiac arrest.

Business overview

Oneg Hakarmel manufactures and sells medical devices for orthopedic surgery, vascular surgery, and emergency medicine. The company's core patent-protected technology includes single-use devices that efficiently displace blood from limbs and prevent its re-entry, primarily through its HemaClear line of sterile surgical products. Additionally, it offers the EED product line for emergency medicine, which facilitates auto-transfusion during severe shock or cardiopulmonary resuscitation. The company's products, including HemaClear, are FDA listed and CE marked, serving the healthcare sector, particularly providers in hospitals and operating rooms, across markets such as the United States and Japan.

Strategic signal

In January 2019, Oneg Hakarmel's HemaShock device garnered significant attention for its potential to improve survival rates in cardiac arrest cases. This highlights the company's commitment to developing innovative solutions in emergency medicine and signals its capability to address critical unmet needs in patient care, potentially expanding its market reach within the critical care segment.

Company Intelligence Q&A

What is Oneg Hakarmel's primary focus?

Oneg Hakarmel focuses on manufacturing and selling products for orthopedic surgery, vascular surgery, and emergency medicine, utilizing patent-protected technology for blood displacement and re-entry prevention in limbs.

When was HemaShock launched?

Oneg Hakarmel launched HemaShock in November 2018. This emergency auto-transfusion tourniquet is designed to rapidly displace blood from limbs into central circulation for patients in severe shock or cardiac arrest.

What certifications do Oneg Hakarmel's products hold?

Oneg Hakarmel's HemaClear products are FDA listed and CE marked, indicating compliance with regulatory standards for medical devices in the United States and Europe.

What was a significant partnership for OHK Medical Devices in Japan?

In June 2013, OHK Medical Devices partnered with Mitsubishi Corp. to launch HemaClear in Japan, expanding its market presence in Asia.

What is the purpose of the EED product line?

The EED product line, developed by Oneg Hakarmel, is used in emergency medicine to auto-transfuse a patient's own blood from their limbs into central circulation during severe shock or cardiopulmonary resuscitation.